Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Completed · Not applicable

Conditions studied: Solid Tumors

In brief

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Key facts

Study ID

NCT00828919

Run by

Pfizer

People needed

52

Starts

2003-03-07

Expected to finish

2023-08-14

Last updated by the study team

2024-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a previous clinical trial
• Patients who were receiving axitinib (AG-013736) tablets at the time their previous trial ended
• Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol should be used to determine stable or responding disease).
• Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

You may not qualify if…

• Patients may not participate in this trial if the conditions for continuing treatment in the previous axitinib (AG-013736) protocol are not met

Where it is running

• UC Irvine Medical Center — Orange, California, United States
• University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center — Orange, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• UCLA Hematology-Oncology-Santa Monica — Santa Monica, California, United States
• University of Chicago Hospitals — Chicago, Illinois, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
• University of Michigan Health System — Ann Arbor, Michigan, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• The Cleveland Clinic — Cleveland, Ohio, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Providence Regional Medical Center Everett - Providence Regional Cancer Partnership — Everett, Washington, United States
• Providence Regional Medical Center Everett — Everett, Washington, United States
• University of Wisconsin - Hospital and Clinics — Madison, Wisconsin, United States
• Fakultni nemocnice Olomouc — Olomouc, Czech Republic, Czechia
• Nemocnice Na Bulovce — Prague, Czechia
• Hopital de la Pitie Salpetriere — Paris, France
• Charité - Universitaetsmedizin Berlin, Charité Campus Mitte — Berlin, Germany
• Semmelweis Egyetem Altalanos Orvostudomanyi Kar — Budapest, Hungary
• Fondazione IRCCS, Istituto Nazionale Tumori, Laboratorio — Milan, Italy
• Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo — Milan, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.